Year: 2018
Type: article
Study design: Observational Study
Abstract: There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17 917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 women were diagnosed with incident breast cancer. Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI] = 0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR = 0.68, 95% CI = 0.32 to 1.47, HR = 0.94, 95% CI = 0.70 to 1.26, and HR = 1.10, 95% CI = 0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately. There was also no association after accounting for hormone therapy use after RRSO. These findings suggest that RRSO should not be considered efficacious for reducing breast cancer risk.
DOI: 10.1093/jnci/djy182
Authors: Mary Beth Terry, Mary B Daly, Kelly Anne Phillips, Xinran Ma, Nur Zeinomar, Nicole Leoce, Gillian S Dite, Robert J MacInnis, Wendy K Chung, Julia A Knight, Melissa C Southey, Roger L Milne, David Goldgar, Graham G Giles, Prue C Weideman, Gord Glendon, Richard Buchsbaum, Irene L Andrulis, Esther M John, Saundra S Buys, John L Hopper
Institutions: Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University, Fox Chase Cancer Center, The University of Melbourne, Peter MacCallum Cancer Centre, Cancer Council Victoria, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Utah, Huntsman Cancer Institute, Stanford Medicine, Stanford Cancer Institute, Stanford University
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,436
Awards: How can the risk of breast cancer be reduced in those with a strong family history of the disease?, G191863333, G2590779331, G2826672938, G325306117, Breast Cancer Family Registry, Clinical Outcomes In Individuals With An Inherited Predisposition To Breast Cancer, G3696798138, Breast Cancer Family Registry Cohort, G429713427, G4500822391, G4779225333, G5305488713, G6681795970, Genes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC, kConFab Clinical Follow-Up Project, G8528577229, G9000192259, NRSA Training Core
OpenAlex ID: W2902069909